Pharma Shifts: New Deals and Controversies in the Health Sector
Published on: Sept. 3, 2025, 2:29 a.m. | Source: Devdiscourse
Recent developments in health include Arrowhead signing a $2 billion deal with Novartis, Zymeworks halting cancer drug development, and a CDC leadership warning against U.S. health policy. Additionally, IQVIA appoints a new financial chief, while Cigna's Evernorth invests in Shields Health. Trump challenges pharma's COVID drug success, and Merck's cholesterol drug achieves trial success.
